L. G. Maldonado, W. C. Busato, L. M. Rossi, T. C. Bonetti, A

Slides:



Advertisements
Similar presentations
Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles  Ryan G. Steward,
Advertisements

Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Age at menarche: a predictor of diminished ovarian function?
Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates  Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.
Comparison of Sperm Motility Measurement Using SQA-V Automated Sperm Analyzer and Conventional Manual Methods  R.K. Sharma, T.M. Said, A. Agarwal  Fertility.
No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.
The normal variabilities of the menstrual cycle
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study  Arianna D'Angelo, M.D., Rachel.
Michael M. Alper, M.D.  Fertility and Sterility 
Raoul Orvieto, M. D. , M. Sc. , Eduard Hod, M. D
Hepatitis and reproduction
Growth rates of ovarian follicles during natural menstrual cycles, oral contraception cycles, and ovarian stimulation cycles  Angela R. Baerwald, Ph.D.,
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial 
Medical treatment of ectopic pregnancy: a committee opinion
Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers  Andrea.
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Oocyte cryopreservation
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant?  H. Browne, A. Armstrong,
Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH)  P. Barriere, T. Freour, D. Masson,
Epidemiology and Adverse Cardiovascular Disease (CVD) Risk Profile of Polycystic Ovarian Syndrome (PCOS): The Kaiser Permanente Polycystic Ovarian Syndrome.
Looking back: egg donors' retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle  Nancy J. Kenney,
Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS)  F. Gonzalez,
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Thickened endometrial stripe in women with post-menopausal bleeding: an association with a common congenital uterine anomaly  M.H. Amols, S.A. El-Nashar,
Fertility and Sterility
Mohamed Fawzy, M. D. , Mohamed Y. AbdelRahman, M. D. , Mohamed H
Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles  Karin.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Fertility and Sterility
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Tania Luisa Stevenson, M.B.Ch.B., Hany Lashen, F.R.C.O.G. 
CDB-2914, a novel selective progesterone receptor modulator, differentially regulates endometrial gene expression in the proliferative phase of the menstrual.
Endocrine gland–derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome.
Immunofluorescence Localization Of Epithelial Cadherin, Cross Reactive With An Antibody Against Human Placental Protein, In Human Preimplantation Embryos 
Effect of weight loss after Roux-en-Y gastric bypass surgery on the male reproductive hormonal profile  A.O. Hammoud, M. Gibson, S.C. Hunt, D. Carrell,
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
P-425 Fertility and Sterility Volume 86, Issue 3, (September 2006)
Single-blastomere whole-genome DNA fingerprinting results in unequivocal embryo identification – a powerful new clinical and diagnostic tool  N.R. Treff,
A case of ovarian hyperstimulation syndrome associated with the methylenetetrahydrofolate reductase mutation gene  Filippo Ferrara, M.D., Francesco Meli,
Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated.
L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing 
Fertility and Sterility: an evaluation
I.R. Silva, A. Lichtenfels, P.N. Saldiva  Fertility and Sterility 
The menopausal transition
Paolo Moghetti, M.D.  Fertility and Sterility 
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination  Deirdre A.
Counteraction during movement of spermatozoa by Trichomonas vaginalis observed by visual image analysis: a possible cause of female infertility  Viroj.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Current evaluation of amenorrhea
Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr  Murat Arslan, M.D.,
Fertility and Sterility
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Fertility and Sterility
Serum anti-Mullerian hormone dynamics during stimulated cycles by aromatase inhibitor anastrozole and clomiphene citrate in women with infertility  H.-H.
Late Stages of Embryo Progression are a Much Better Predictor of Clinical Pregnancy Than Early Cleavage in ICSI and IVF Cycles With Blastocyst-Stage Transfer 
Diane De Neubourg, M. D. , Kathelijne Mangelschots, B. Sc
Fertility and Sterility
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Contact among families who share the same sperm donor
Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome  Kris Poppe, M.D., Ph.D., David Unuane,
Presentation transcript:

Estradiol Levels on Day 3 and 5 as an Early Predictor of Ovarian Hyperstimulation Syndrome  L.G. Maldonado, W.C. Busato, L.M. Rossi, T.C. Bonetti, A. Iaconelli, E. Borges  Fertility and Sterility  Volume 84, Pages S273-S274 (September 2005) DOI: 10.1016/j.fertnstert.2005.07.710 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

Legend: Y = percentage of risk to OHSS Exp = exponential D3 = E2 level on day 3 of menstrual cycle (pg / mL) D5 = E2 level on day 5 of menstrual cycle (pg / mL) In this study, we have been tested the formula efficiency using a specific protocol with microdose of recombinant hCG to COS. Fertility and Sterility 2005 84, S273-S274DOI: (10.1016/j.fertnstert.2005.07.710) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.